Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: Targeted delivery and ROS-responsive release of Resolvin D1 by platelet chimeric liposome ameliorates myocardial ischemia–reperfusion injury

Fig. 5

PLP-RvD1 promotes efferocytosis, angiogenesis and the synthesis of SPMs in vivo. A The efferocytosis ability of macrophages to apoptotic cardiomyocytes in vivo after PBS, LP-RvD1 or PLP-RvD1 treatment was detected by fluorescence microscopy images and C the efferocytosis index was calculated. (n = 6 per group). Red, F4/80; yellow, Desmin, a cardiomyocyte marker. Scalar bar, 20 µm. B CLSM images of CD31 + signals in MI/R injured murine heart sections after PBS, LP-RvD1, or PLP-RvD1 administered and D statistically analyzed by ImageJ (n = 6 per group). Red, cTnT; Green, CD31. Scalar bar, 50 µm. EH Determination of related SPMs molecules (RvD1, RvD2, RvE1, LXA4) in cardiac tissue homogenate by ELISA after treated with PBS, LP-RvD1 or PLP-RvD1, respectively (n = 6 per group). Results are presented as mean ± SD. NSP > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page